IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update
Saint Laurent, Quebec--(Newsfile Corp. - March 11, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) (the "Company") today announced financial results for its fiscal year ended December 31, 2013 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated. "2013 was a challenging and exciting year for IntelGenx," said Rajiv Khosla, President and CEO of IntelGenx. "We made significant progress with the filing of the NDA for our anti-migraine film...
2014-03-11 8:30 AM EDT
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
Saint Laurent, Quebec--(Newsfile Corp. - March 3, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL") of the U.S. Food and...
2014-03-03 8:00 AM EST
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
Saint Laurent, Quebec--(Newsfile Corp. - February 26, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA") from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been...
2014-02-26 8:05 AM EST
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
Saint Laurent, Quebec--(Newsfile Corp. - February 24, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm™ tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product. This was a randomized, two-period, two-way crossover study in healthy male subjects....
2014-02-24 8:00 AM EST
IntelGenx and RedHill Biopharma Receive Complete Response Letter from FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data In light of the increased regulatory clarity, IntelGenx and RedHill plan to rapidly advance ongoing discussions with potential partners for the commercialization of their Anti-Migraine "VersaFilm™" Oral Film...
2014-02-04 8:10 AM EST
IntelGenx Announces Additional Development and Commercialization Agreement with Par Pharmaceutical, Inc. for Two More Products
Saint Laurent, Quebec--(Newsfile Corp. - January 13, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) (“IntelGenx” or the “Company”), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. ("Par") for two new products utilizing IntelGenx' proprietary oral drug delivery platforms. Under the terms of the agreement, Par has obtained certain exclusive rights to...
2014-01-13 8:00 AM EST
IntelGenx Grants Stock Options
Saint Laurent, Quebec--(Newsfile Corp. - January 9, 2014) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx", or the "Company") announced today that the Company's board of directors granted options to acquire 120,000 common shares under the 2006 Stock Option Plan, as amended. The options were granted to the President and Chief Executive Officer, Dr. Rajiv Khosla in accordance with his employment agreement.The options have an exercise price of CAD$0.60 and expire on January...
2014-01-09 11:31 AM EST
IntelGenx Closes $3.5 Million Public Offering
Saint Laurent, Quebec--(Newsfile Corp. - December 16, 2013) - IntelGenx Technologies Corp. (OTCQX: IGXT) (TSXV: IGX) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm™ technology, as well as oral controlled-release products, announced today that it has closed a registered public offering to raise gross proceeds of approximately $3.5 million.As previously announced, on December 12, 2013...
2013-12-16 3:31 PM EST
IntelGenx Announces Public Offering of $3,500,000 of Common Stock
Saint Laurent, Quebec--(Newsfile Corp. - December 12, 2013) - IntelGenx Technologies Corp. (OTCQX: IGXT) (TSXV: IGX) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm™ technology, as well as oral controlled-release products, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $3.5 million of securities in a registered...
2013-12-12 8:00 AM EST
IntelGenx Grants Stock Options
Saint Laurent, Quebec--(Newsfile Corp. - December 4, 2013) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx", or the "Company") announced today that the Company's board of directors granted options to acquire 175,000 common shares under the 2006 Stock Option Plan as amended. Of the total stock options granted, 75,000 were granted to Ian Troup, a non-employee director and 100,000 were granted to Paul A. Simmons, the Chief Financial Officer.The options have an exercise price...
2013-12-04 3:16 PM EST